Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Research

Hangzhou Tigermed Consulting Co., Ltd. operates as a prominent contract research organization (CRO), delivering an extensive array of services across the People's Republic of China and globally. Its operations are strategically segmented into Clinical Trial Solutions and Clinical-related and Laboratory Services. The firm's comprehensive offerings include critical regulatory support like submission and approval navigation, medical translation, and Good Manufacturing Practice (GMP) consulting. For clinical development, Tigermed provides end-to-end services, encompassing medical science guidance, early to late-phase study execution, medical monitoring, meticulous project management, efficient patient recruitment, and stringent quality management systems. Biometrics capabilities cover data management, advanced biostatistics, and precise statistical programming. Integrated technology solutions are also central, featuring site management, pharmacovigilance, independent auditing and training, medical imaging, bespoke clinical trial systems, central laboratory services, pre-clinical research support, and assistance for research hospitals. Moreover, the company specializes in medical device and in vitro diagnostics (IVD) services, handling everything from product testing and regulatory submissions to clinical evaluations, trial conduct, GMP certification, and preparation for EU MDR and IVDR compliance. Further specialized services include post-marketing studies, real-world evidence generation, and clinical trials specifically for vaccines. Hangzhou Tigermed Consulting Co., Ltd. was founded in 2004.

Open Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.